Nexalin Technology Regains Compliance with Nasdaq Minimum Bid Price Requirement; Nasdaq Hearings Panel Grants Request for Continued Listing
Company remains focused on its transition toward commercial revenue generation and the advancement of its U.S. clinical programs Company remains focused on